The Biotechnology Revolution: News from Nuvectis Pharma and Revolution Medicines Publication

Nuvectis Pharma
Nuvectis Pharma (NVCT) is a biopharmaceutical company focused on developing innovative precision targeted drugs capable of treating cancers that have yet to find treatments. The Company’s pipeline comprises two drug candidates, NXP800 and NXP900.

NXP800  is an oral small molecule in Phase 1b clinical investigating the product activity and potential treatment of platinum resistant ARID1a-mutated ovarian carcinoma . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.